News

The companies can now offer marketing and commercialization rights for Ondansetron ODF in Europe and selected Non-European countries, either through global, regional or local license agreements. Ondansetron ODF

Following the acquisition, inVentiv Health’s clinical segment comprises i3, along with inVentiv’s existing clinical businesses and PharmaNet Development Group. i3 CEO Glenn Bilawsky said for their clients, this

Zutripro oral solution and Rezira oral solution, to be marketed by Cypress Pharma’s subsidiary Hawthorn Pharmaceuticals, are indicated for the treatment of cough and other symptoms linked with

The partnership addresses the industry need for IRTsolutions to optimize clinical trial patient randomization, drug supply management and clinical trial status monitoring and reporting. FormsVision was formed to

The company expects to recruit around 880 patients in over 40 hospitals in 9 countries. The aim of this study is to establish Multikine as a first-line standard

The company intends to start shipping upon final authorization by the Drug Enforcement Administration. Divine Skin chairman and CEO Daniel Khesin said since Divine Skin focuses on underserved

Recently, Cortex has received $1,000,000 from Servier for the option to expand its rights for CX1632. As per the terms of the agreement, if Servier exercises the option

Earlier in December 2008, ProStrakan Group, a wholly owned subsidiary of Kyowa Hakko Kirin, has licensed Canadian rights for Abstral to Paladin. Paladin Labs president and CEO Jonathan

Cacciuttolo was MedImmune, Medarex Technical Operations vice president, and was recently president and CEO of PERCIVIA. The company also appointed Ben Machielse and Robert Gailus to the Board